- Home
- JFB vs COEP Comparison
JFB vs COEP Comparison
Compare JFB & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFB
- COEP
- Stock Information
- Founded
- JFB 2014
- COEP 2017
- Country
- JFB United States
- COEP United States
- Employees
- JFB N/A
- COEP N/A
- Industry
- JFB
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JFB
- COEP Health Care
- Exchange
- JFB NYSE
- COEP Nasdaq
- Market Cap
- JFB 37.3M
- COEP 30.5M
- IPO Year
- JFB 2025
- COEP N/A
- Fundamental
- Price
- JFB $4.14
- COEP $12.24
- Analyst Decision
- JFB
- COEP
- Analyst Count
- JFB 0
- COEP 0
- Target Price
- JFB N/A
- COEP N/A
- AVG Volume (30 Days)
- JFB 15.6K
- COEP 25.5K
- Earning Date
- JFB 01-01-0001
- COEP 05-09-2025
- Dividend Yield
- JFB N/A
- COEP N/A
- EPS Growth
- JFB N/A
- COEP N/A
- EPS
- JFB 0.02
- COEP N/A
- Revenue
- JFB $23,087,885.00
- COEP N/A
- Revenue This Year
- JFB N/A
- COEP N/A
- Revenue Next Year
- JFB N/A
- COEP N/A
- P/E Ratio
- JFB $280.04
- COEP N/A
- Revenue Growth
- JFB N/A
- COEP N/A
- 52 Week Low
- JFB $3.39
- COEP $2.31
- 52 Week High
- JFB $4.87
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- JFB N/A
- COEP 69.07
- Support Level
- JFB N/A
- COEP $9.16
- Resistance Level
- JFB N/A
- COEP $11.69
- Average True Range (ATR)
- JFB 0.00
- COEP 0.48
- MACD
- JFB 0.00
- COEP 0.30
- Stochastic Oscillator
- JFB 0.00
- COEP 96.64
About JFB JFB CONSTRUCTION HOLDINGS
JFB Construction Holdings is a commercial and residential real estate construction and development company. It is engaged in retail corporate buildouts, multifamily community developments and luxury residential homes, with a focus on fostering long-term relationships with clients, partners, and communities. The company operates in three distinct business segments: Commercial Construction, Residential Construction, and Real Estate Development. Key revenue is generated from Commercial Construction: This segment includes all activities related to the construction of commercial properties such as office buildings, retail spaces, and industrial facilities.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.